Marc Wilson - Jan 2, 2024 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role
CFO
Signature
/s/ Marc Wilson
Stock symbol
CRNX
Transactions as of
Jan 2, 2024
Transactions value $
-$261,900
Form type
4
Date filed
1/4/2024, 04:43 PM
Previous filing
Nov 3, 2023
Next filing
Mar 6, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRNX Common Stock Options Exercise $92.8K +10K +10.41% $9.28 106K Jan 2, 2024 Direct F1
transaction CRNX Common Stock Sale -$355K -10K -9.43% $35.47 96.1K Jan 2, 2024 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRNX Non-qualified stock option (Right to Buy) Options Exercise $0 -10K -16.34% $0.00 51.2K Jan 2, 2024 Common Stock 10K $9.28 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Includes 454 shares acquired under the Issuer's Employee Stock Purchase.
F2 The sale reported in this Form 4 was effected automatically pursuant to a Rule 10b5-1 trading plan.
F3 The common stock was sold by the Reporting Person in open market transactions on the transaction date with a volume weighted average sales price of $35.47 per share. The range of sales prices on the transaction date was $34.41 to $36.07 per share. Detailed information on the exact number of shares can be obtained from the issuer upon request.
F4 1/48th of the shares subject to the option vested on June 25, 2018, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.